EuBiologics Co., Ltd.
http://www.eubiologics.com/en/main/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From EuBiologics Co., Ltd.
How IVI Is Helping To Shape Korea’s Vaccine Ambitions
International Vaccine Institute Director General Jerome Kim talks to Scrip about the significance of South Korea's vaccine hub strategy and IVI's role, as well as the wider progress in the sector in the country.
Korean COVID-19 Contenders Still Racing Toward Finish Line
Hyundai Bioscience’s niclosamide-based oral antiviral moves into Phase II, joining other Korean COVID-19 treatment candidates in the pivotal trial stages, while SK Bioscience’s Phase III recombinant protein vaccine gears up for global market entry.
EuBiologics On COVID-19 Vaccine And Fulfilling Public Health Mission
EuBiologics CEO Yeong Ok Baik sat down with Scrip at CPhI Korea to talk about why he wants to develop vaccines for global public health needs and what plans are in store for its late-stage recombinant protein candidate for COVID-19.
Korea Kick-Starts Major Consortium For Next-Gen mRNA Vaccines
South Korea is stepping on the gas to develop its own mRNA COVID-19 vaccine and eventually next generation mRNA platform technology for use in other diseases, to meet its goal of becoming a global vaccine hub.
Company Information
- Industry
- Contract Research, Toxicology Testing-CRO
- Distributors
-
Pharmaceuticals
- Vaccines
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice